This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lynch, R. A. Articles by Frank, D. A. Search for Related Content PubMed PubMed Citation Articles by Lynch, R. A. Articles by Frank, D. A.

A Small-Molecule Enhancer of Signal Transducer and Activator of Transcription 1 Transcriptional Activity Accentuates the Antiproliferative Effects of IFN- in Human Cancer Cells

Department of Medical Oncology, Dana-Farber Cancer Institute, Departments of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts

Requests for reprints: David A. Frank, Department of Medical Oncology, Mayer 522B, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. Phone: 617-632-4714; Fax: 1-617-632-6356; E-mail: david_frank{at}dfci.harvard.edu.

The transcription factor signal transducer and activator of transcription (STAT) 1 can mediate antiproliferative and proapoptotic effects in cancer cells, and a number of mechanisms have been found whereby STAT1 signaling is attenuated in tumors thereby increasing their malignant behavior. Thus, enhancing gene transcription mediated by STAT1 may be an effective approach to cancer therapy. A high-throughput screen was developed to identify molecules that could enhance STAT1-dependent gene expression. Through this approach, it was found that 2-(1,8-naphthyridin-2-yl)phenol (2-NP) caused a 2-fold increase in STAT1-dependent reporter gene expression compared with that seen with maximally effective concentrations of IFN- alone. This effect was specific to STAT1 because 2-NP had no effect on unrelated transcription factors such as nuclear factor (NF) B or the highly homologous transcription factor STAT3. STAT1-dependent gene activation was enhanced by this compound in a variety of human and murine cell lines and was independent of the stimulus used. Furthermore, 2-NP enhanced the expression of the bona fide endogenous STAT1 target gene interferon regulatory factor 1. 2-NP increased the duration of STAT1 tyrosine phosphorylation in response to IFN-, and this may underlie its enhancement of STAT1-dependent transcription. Reflecting the fact that STAT1 can exert tumor-suppressive effects, 2-NP enhanced the ability of IFN- to inhibit the proliferation of human breast cancer and fibrosarcoma cells. Tumor cells lacking STAT1 were unaffected by either IFN- or 2-NP. These findings indicate that enhancement of STAT1 transcriptional activity may have utility in anticancer therapies, and that cell-based screens for modulators of transcription factor function can be a useful approach for drug discovery. [Cancer Res 2007;67(3):1254–61]

This article has been cited by other articles:

				S. R. Walker, E. A. Nelson, L. Zou, M. Chaudhury, S. Signoretti, A. Richardson, and D. A. Frank Reciprocal Effects of STAT5 and STAT3 in Breast Cancer Mol. Cancer Res., June 1, 2009; 7(6): 966 - 976. [Abstract] [Full Text] [PDF]

				K. M. Sakamoto and D. A. Frank CREB in the Pathophysiology of Cancer: Implications for Targeting Transcription Factors for Cancer Therapy Clin. Cancer Res., April 15, 2009; 15(8): 2583 - 2587. [Abstract] [Full Text] [PDF]

				K. Nakamura, Y. Komagiri, T. Kojo, and M. Kubokawa Delayed and acute effects of interferon-{gamma} on activity of an inwardly rectifying K+ channel in cultured human proximal tubule cells Am J Physiol Renal Physiol, January 1, 2009; 296(1): F46 - F53. [Abstract] [Full Text] [PDF]

				E. A. Nelson, S. R. Walker, A. Kepich, L. B. Gashin, T. Hideshima, H. Ikeda, D. Chauhan, K. C. Anderson, and D. A. Frank Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3 Blood, December 15, 2008; 112(13): 5095 - 5102. [Abstract] [Full Text] [PDF]

				C. Desmedt, B. Haibe-Kains, P. Wirapati, M. Buyse, D. Larsimont, G. Bontempi, M. Delorenzi, M. Piccart, and C. Sotiriou Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes Clin. Cancer Res., August 15, 2008; 14(16): 5158 - 5165. [Abstract] [Full Text] [PDF]

				D. A Frank Targeting Transcription Factors for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 335 - 341. [Abstract] [Full Text] [PDF]